Pancreatic cancer: a persistently challenging prognosis - a single center three-year retrospective study
Modifiable and non-modifiable risk factors significantly raise the incidence of pancreatic cancer. Therefore, employing a multidisciplinary approach to detect the disease in its early stages and optimize personalized treatment plans can enhance patient outcomes. At the same time, traditional oncological treatments improve survival and quality of life, but newer approaches, such as immunotherapy combined with conventional radiotherapy, chemotherapy, molecular targeted therapy, and other diverse treatment modalities, have the potential to further extend survival.
Authors
- Claudia Hagiu
- L Munteanu
- Paul-Cristian Borz
- Ana Maria Fiț
- Simona Gurzu (ORCID: https://orcid.org/0000-0003-3968-5118)
- M.B. Borz (ORCID: https://orcid.org/0000-0002-7361-7031)
- Toader Zaharie
- Oliviu-Cristian Borz
Institutions
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș (RO)
- Institutul Regional de Gastroenterologie Prof. Dr. Octavian Fodor (RO)
- Institute of Oncology Prof. Dr. Ion Chiricuta (RO)
- Spitalul Clinic Judetean de Urgenta Târgu Mureş (RO)
Publication Details
- Journal
- Medicine and Pharmacy Reports
- Published
- 2025-05-19
- DOI
- https://doi.org/10.15386/mpr-2848
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05